Who is sponsoring NCT02159651?

NCT02159651 is sponsored by Astellas Pharma Inc.

What drugs are being tested in NCT02159651?

Interventions in NCT02159651: tacrolimus.

Is NCT02159651 still recruiting?

NCT02159651 is currently completed. Last updated 22 October 2024.

Last reviewed 2024-10-22 · How we verify

NCT02159651

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Survey for Long-term Use of Prograf Capsules in Patient With Interstitial Pneumonia

Completed Last updated 22 October 2024

What this trial tests

trial testing tacrolimus in Interstitial Pneumonia Associated With Polymyositis/Dermatomyositis in 179 participants. Completed in 23 December 2019.

Timeline

1 April 2014

Primary endpoint
23 December 2019

23 December 2019

Quick facts

Lead sponsor	Astellas Pharma Inc
Status	Completed
Study type	OBSERVATIONAL
Enrollment	179
Start date	1 April 2014
Primary completion	23 December 2019
Estimated completion	23 December 2019
Sites	8 locations across Japan

Drugs / interventions tested

tacrolimus (TACROLIMUS) — full drug profile →

Conditions studied

Interstitial Pneumonia Associated With Polymyositis/Dermatomyositis — all drugs for Interstitial Pneumonia Associated With Polymyositis/Dermatomyositis →

Sponsor

Astellas Pharma Inc — full company profile →

Who can join

Eligibility, any sex, with Interstitial Pneumonia Associated With Polymyositis/Dermatomyositis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is to evaluate the safety and the efficacy of Prograf in patients with interstitial pneumonia associated with polymyositis / dermatomyositis in acute clinical setting.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The Role of Macrophages in Connective Tissue Disease-Associated Interstitial Lung Disease: Focusing on Molecular Mechanisms and Potential Treatment Strategies.
Tseng CC, Sung YW, Chen KY, Wang PY, et al · · 2023 · cited 15× · PMID 37569370 · DOI 10.3390/ijms241511995
Tacrolimus in Patients With Interstitial Pneumonia Associated With Polymyositis or Dermatomyositis: Interim Report of Postmarketing Surveillance in Japan.
Kuwana M, Wakasugi N, Furuya T, Uno S, et al · · 2022 · cited 5× · PMID 35428708 · DOI 10.3899/jrheum.210322

Verify or expand the search:

Other trials of tacrolimus

Trials testing the same drug.

NCT05294666 — Evaluation of 0.05% CsA and 0.1% FK506 Eye Drops in Ocular GVHD Treatment · Phase 4 · completed
NCT03737708 — A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA) · Phase 4 · completed
NCT03178149 — A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due · Phase 1 · recruiting
NCT03540472 — Tacrolimus Treatment for Refractory PRCA · Phase 4 · unknown
NCT03465969 — A Study to Compare the Finger Prick Whole Blood MITRA Assay Method With the Established Venepuncture Whole Blood Method · Phase 4 · completed

Other Astellas Pharma Inc trials

Trials by the same sponsor.

NCT07318714 — A Study of ASP2246 for People Who Have Movement Problems Caused by Brain Injury After a Stroke · Phase 1, PHASE2 · recruiting
NCT07094204 — A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors · Phase 1 · recruiting
NCT06970665 — A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Ma · Phase 4 · recruiting
NCT06364696 — A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors · Phase 1 · active not recruiting
NCT06206421 — A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through Menopause · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02159651 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Astellas Pharma Inc
Last refreshed: 22 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02159651.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing